Literature DB >> 20559983

Ventricular assist devices: history, patient selection, and timing of therapy.

Daniel G Tang1, Philip E Oyer, Hari R Mallidi.   

Abstract

Timing of therapy and selection of patients in the use of ventricular assist devices (VADs) can be difficult. In general, consideration for VAD implantation is appropriate in patients with endstage heart failure who are failing optimal medical therapy and in whom no alternative traditional surgical treatment options are available. However, identifying when a particular patient has reached this point is not always straightforward. There are a broad range of medical and surgical therapies for patients with overt heart failure, and this armamentarium is constantly expanding. The risks, benefits, and expected outcomes with VAD therapy have also undergone dramatic changes over the last decade. Advances in technology have led to a proliferation of newer generation devices that are smaller, lighter, easier to implant, and more reliable than previous generation devices. This, in turn, has led to a markedly improved risk-benefit ratio, with increased durability and reduced morbidity. The indications for the implantation of ventricular assist devices have also evolved over the last several years, and specific patient presentations and goals of therapy have led to specific indications. Device therapy has traditionally been classified as bridge to recovery, bridge to transplantation, and destination therapy. However, such designations may not be well defined at the time of implantation, and recovery and response following initiation of VAD support may allow patients to change from one classification to another. The current data regarding indications and timing of device implantation are reviewed.

Entities:  

Mesh:

Year:  2009        PMID: 20559983     DOI: 10.1007/s12265-009-9098-5

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  48 in total

1.  Ventricular assist systems for temporary life support: device readiness testing.

Authors:  A S Berson
Journal:  IEEE Eng Med Biol Mag       Date:  1988

2.  Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation.

Authors:  K D Aaronson; J S Schwartz; T M Chen; K L Wong; J E Goin; D M Mancini
Journal:  Circulation       Date:  1997-06-17       Impact factor: 29.690

3.  Orthotopic cardiac prosthesis for two-staged cardiac replacement.

Authors:  D A Cooley; D Liotta; G L Hallman; R D Bloodwell; R D Leachman; J D Milam
Journal:  Am J Cardiol       Date:  1969-11       Impact factor: 2.778

4.  Thoratec VAD system as a bridge to heart transplantation.

Authors:  D J Farrar; J H Lawson; P Litwak; G Cederwall
Journal:  J Heart Transplant       Date:  1990 Jul-Aug

5.  Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation.

Authors:  O H Frazier; E A Rose; M C Oz; W Dembitsky; P McCarthy; B Radovancevic; V L Poirier; K A Dasse
Journal:  J Thorac Cardiovasc Surg       Date:  2001-12       Impact factor: 5.209

6.  The Seattle Heart Failure Model: prediction of survival in heart failure.

Authors:  Wayne C Levy; Dariush Mozaffarian; David T Linker; Santosh C Sutradhar; Stefan D Anker; Anne B Cropp; Inder Anand; Aldo Maggioni; Paul Burton; Mark D Sullivan; Bertram Pitt; Philip A Poole-Wilson; Douglas L Mann; Milton Packer
Journal:  Circulation       Date:  2006-03-13       Impact factor: 29.690

7.  The use of continuous milrinone therapy as bridge to transplant is safe in patients with short waiting times.

Authors:  Christian Assad-Kottner; David Chen; Jama Jahanyar; Francisco Cordova; Nathan Summers; Matthias Loebe; Ramanna Merla; Keith Youker; Guillermo Torre-Amione
Journal:  J Card Fail       Date:  2008-11-05       Impact factor: 5.712

8.  Tricuspid annular motion as a predictor of severe right ventricular failure after left ventricular assist device implantation.

Authors:  Sarinya Puwanant; Karen K Hamilton; Charles T Klodell; James A Hill; Richard S Schofield; Timothy S Cleeton; Daniel F Pauly; Juan M Aranda
Journal:  J Heart Lung Transplant       Date:  2008-10       Impact factor: 10.247

9.  Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial.

Authors:  Joseph G Rogers; Javed Butler; Steven L Lansman; Alan Gass; Peer M Portner; Michael K Pasque; Richard N Pierson
Journal:  J Am Coll Cardiol       Date:  2007-08-06       Impact factor: 24.094

Review 10.  Patient selection for left ventricular assist device therapy.

Authors:  Keith D Aaronson; Himanshu Patel; Francis D Pagani
Journal:  Ann Thorac Surg       Date:  2003-06       Impact factor: 4.330

View more
  2 in total

1.  Cardiovascular implantable device infections.

Authors:  George M Viola; Rabih O Darouiche
Journal:  Curr Infect Dis Rep       Date:  2011-08       Impact factor: 3.725

Review 2.  Life-saving devices reach the end of life with heart failure.

Authors:  Daniel D Matlock; Lynne Warner Stevenson
Journal:  Prog Cardiovasc Dis       Date:  2012 Nov-Dec       Impact factor: 8.194

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.